TY - JOUR
T1 - Selenium supplementation in HIV-infected individuals
T2 - A systematic review of randomized controlled trials
AU - Muzembo, Basilua Andre
AU - Ngatu, Nlandu Roger
AU - Januka, Khatiwada
AU - Huang, Hsiao Ling
AU - Nattadech, Choomplang
AU - Suzuki, Tomoko
AU - Wada, Koji
AU - Ikeda, Shunya
N1 - Funding Information:
The authors would like to thank Mr. Matthew McLaughlin from the International University of Health and Welfare and Mrs. Mansongi Biyela Carine for their helpful suggestions through the preparation and composition of this manuscript.
Publisher Copyright:
© 2019 European Society for Clinical Nutrition and Metabolism
PY - 2019/12
Y1 - 2019/12
N2 - Background & aim: HIV infection has been linked to selenium deficiency which, in turn, is thought to be associated with a high risk of tuberculosis and mortality in HIV-infected patients. Furthermore, several trials have reported the beneficial effects of selenium supplementation in patients with HIV. However, the evidence remains inconclusive. Our study aimed to investigate whether daily selenium supplementation in patients infected with HIV delays the progression of HIV infection. Methods: A systematic review was performed using EMBASE and Medline databases from January 2000 to June 2018. We included randomized clinical trials in adults comparing selenium with placebo and reporting outcomes including its effect on HIV viral load and cluster of differentiation 4 cell count (CD4). Results: Six out of the 507 retrieved articles that met the inclusion criteria were used in this review. Reviewed studies show that daily supplementation with 200 μg selenium may improve the rate of cluster of differentiation 4 (CD4) count. The length of selenium supplementation and follow-up varied from 9 to 24 months. Supplements were well tolerated in all reviewed studies. Whether daily selenium supplementation in HIV-infected persons suppresses HIV-infection requires further investigation as existing data are heterogeneous. Conclusions: We found some clinical evidence that selenium supplementation can delay CD4 decline in HIV-infected patients, thus prolonging the onset of AIDS. However, we did not find quantifiable evidence that selenium supplementation suppresses or reduces HIV viral load.
AB - Background & aim: HIV infection has been linked to selenium deficiency which, in turn, is thought to be associated with a high risk of tuberculosis and mortality in HIV-infected patients. Furthermore, several trials have reported the beneficial effects of selenium supplementation in patients with HIV. However, the evidence remains inconclusive. Our study aimed to investigate whether daily selenium supplementation in patients infected with HIV delays the progression of HIV infection. Methods: A systematic review was performed using EMBASE and Medline databases from January 2000 to June 2018. We included randomized clinical trials in adults comparing selenium with placebo and reporting outcomes including its effect on HIV viral load and cluster of differentiation 4 cell count (CD4). Results: Six out of the 507 retrieved articles that met the inclusion criteria were used in this review. Reviewed studies show that daily supplementation with 200 μg selenium may improve the rate of cluster of differentiation 4 (CD4) count. The length of selenium supplementation and follow-up varied from 9 to 24 months. Supplements were well tolerated in all reviewed studies. Whether daily selenium supplementation in HIV-infected persons suppresses HIV-infection requires further investigation as existing data are heterogeneous. Conclusions: We found some clinical evidence that selenium supplementation can delay CD4 decline in HIV-infected patients, thus prolonging the onset of AIDS. However, we did not find quantifiable evidence that selenium supplementation suppresses or reduces HIV viral load.
KW - AIDS
KW - HIV
KW - Selenium
KW - Selenium deficiency
KW - Selenium supplementation
KW - Selenomethionine
UR - http://www.scopus.com/inward/record.url?scp=85072767109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072767109&partnerID=8YFLogxK
U2 - 10.1016/j.clnesp.2019.09.005
DO - 10.1016/j.clnesp.2019.09.005
M3 - Review article
C2 - 31677697
AN - SCOPUS:85072767109
VL - 34
SP - 1
EP - 7
JO - Clinical Nutrition ESPEN
JF - Clinical Nutrition ESPEN
SN - 2405-4577
ER -